biowaiver

Proving two products are equivalent normally means dosing human volunteers and measuring drug in their blood — expensive, slow, and ethically not trivial. A biowaiver is regulators' permission to skip that in-vivo study and rely on laboratory dissolution data instead, when the science says the human study would add no real information. In effect, the beaker stands in for the volunteer.

The most common form is the BCS-based biowaiver. For an immediate-release oral product whose drug is BCS Class I (high solubility, high permeability) — and, under tighter conditions, Class III (high solubility, low permeability) — regulators may grant bioequivalence on the basis that the test and reference products both dissolve rapidly and similarly in standardized media across the physiological pH range, and that the excipients do not affect absorption. The logic is that if dissolution is fast and the drug is freely absorbed, the formulation cannot meaningfully change the outcome in the body.

Biowaivers also apply in other situations — additional strengths of a product whose pivotal strength has already passed a bioequivalence study (proportional formulations), and certain post-approval manufacturing changes supported by a validated IVIVC for modified-release products. The boundaries are carefully drawn: narrow-therapeutic-index drugs, formulations with absorption-altering excipients, and Class II or IV drugs generally do not qualify, because there the in-vivo study still carries information a dissolution test cannot replace.